Quality Care
Also, VUNO has obtained regulatory clearance in South Korea for its AI-based screening solution for kidney failure.
Trained on two million skin images, it can perform a range of clinical tasks unlike current models.
The two organizations will collaborate to accelerate the company's growth and enhance proactive care and management of chronic diseases.
The partners will develop and clinically validate an AI tool that integrates into EHRs to accelerate the diagnosis of hypophosphatasia, a rare genetic bone disorder.
The company will grow its clinical team and expand its offerings across GI partner clinics representing 700 physicians, after an 800% rise in patient volume.
Dr. Jing Wang, dean of Florida State University’s College of Nursing, joins MobiHealthNews to discuss "nursifying AI."
Also, fellow Korean medical AI companies have obtained regulatory approvals across global markets.
40% of their time is spent on manually collecting data, which the tool would assist in reducing.
The model could be deployed as a decision support tool in emergency departments.
The Southern New Jersey health system discovered that certain data stored in its systems was potentially acquired without authorization.